Grifols SA (GRFS)
9.44
-0.11
(-1.15%)
USD |
NASDAQ |
Nov 15, 14:27
Grifols Free Cash Flow (Quarterly)
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2021 | 107.05M |
| March 31, 2021 | 142.04M |
| December 31, 2020 | 162.18M |
| September 30, 2020 | 297.89M |
| June 30, 2020 | 372.97M |
| March 31, 2020 | 20.94M |
| December 31, 2019 | 81.11M |
| September 30, 2019 | 134.91M |
| June 30, 2019 | 242.32M |
| March 31, 2019 | -283.00M |
| December 31, 2018 | 268.70M |
| September 30, 2018 | 97.39M |
| June 30, 2018 | 100.29M |
| March 31, 2018 | 41.03M |
| December 31, 2017 | 165.70M |
| September 30, 2017 | 166.11M |
| June 30, 2017 | 171.50M |
| March 31, 2017 | 84.21M |
| December 31, 2016 | 96.01M |
| September 30, 2016 | 146.13M |
| June 30, 2016 | 50.69M |
| Date | Value |
|---|---|
| March 31, 2016 | -4.418M |
| December 31, 2015 | 269.97M |
| September 30, 2015 | -188.51M |
| June 30, 2015 | 474.46M |
| March 31, 2015 | -360.88M |
| December 31, 2014 | 326.49M |
| September 30, 2014 | 240.66M |
| June 30, 2014 | 250.82M |
| March 31, 2014 | 102.13M |
| December 31, 2013 | 228.72M |
| September 30, 2013 | 52.49M |
| June 30, 2013 | 196.35M |
| March 31, 2013 | 79.13M |
| December 31, 2012 | 154.10M |
| September 30, 2012 | 109.70M |
| June 30, 2012 | 119.84M |
| March 31, 2012 | 54.74M |
| December 31, 2011 | 146.73M |
| September 30, 2011 | -10.54M |
| June 30, 2011 | -89.51M |
| March 31, 2011 | 37.44M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
20.94M
Minimum
Mar 2020
372.97M
Maximum
Jun 2020
169.17M
Average
142.04M
Median
Mar 2021
Free Cash Flow (Quarterly) Benchmarks
| Cellectis SA | -6.634M |
| Adaptimmune Therapeutics PLC | 46.64M |
| Akari Therapeutics PLC | -4.894M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | -62.66M |